Receiving of SARS-CoV-2/COVID-19 convalescent plasma in 2020–2021 in context of activity of Regional Center of Blood Donation and Blood Treatment in Bydgoszcz, Poland
Abstract
Introduction: We analyzed SARS-CoV-2/COVID-19 convalescent plasma (CCP) production in the process of qualifying donors-convalescents, plasma collection and dispensing from the Regional Center of Blood Donation and Blood Treatment (RCKiK, Regionalne Centrum Krwiodawstwa i Krwiolecznictwa) in Bydgoszcz in the light of Polish national data.
Material and methods: This retrospective analysis based on the RCKiK documentation covers the first year of convalescent plasma production and use, i.e. from 1 May 2020 to 30 April 2021. Evaluations of the qualifying process for convalescent donors, plasma collection, and dispensing to hospitals were carried out. The data was analyzed in relation to data from all over Poland provided by the National Blood Center.
Results: In the 12 months ending on 30 April, 2021, 121,896.2 CCP units were acquired in total in 21 Regional Blood Donation and Treatment Centers. Of these, 14,683 units (12%) were acquired in Bydgoszcz, which places RCKiK Bydgoszcz in first place in Poland. The majority of donors were men, and most men were multiple donors, but most women were first-time donors. Most donors donated blood once, but 28.8% of donors donated at least twice. Most donations took place between December 2020 and March 2021, i.e. after the peak of the second and during the third wave of the pandemic. Nearly all the CCP preparations were dispensed to 29 hospitals in the Kuyavian-Pomeranian Voivodeship, and about 0.4% to other voivodeships.
Conclusions: In the period from 1 May 2020 to 30 April 2021, the RCKiK in Bydgoszcz was the most active center in Poland for obtaining, producing and distributing plasma from people who were convalescing. In the plasma collection process, a very high level of commitment among of RBC personnel and donors was found, expressed in an increased number of donations. A relatively high proportion of donors were first-time and repeat multiple donors, although most donors gave only one donation. The mean anti-SARS-CoV-2 antibodies titer remained at a comparable level up to 150 days after disease.
Keywords: COVID-19 convalescent plasma (CCP)COVID-19SARS-CoV-2Regional Blood Donation and Blood Treatment Center
References
- World Health Organization Situation Report. World Health Organization Situation Report. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (May 27, 2022).
- Gągola K, Styczyński J. The use of convalescent plasma in therapy of patients with COVID-19. Acta Haematol Pol. 2020; 53(5): 3XX–3XX.
- Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfus Med. 2005; 15(4): 269–276.
- Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion. 2016; 56(12): 2948–2952.
- Hindawi SI, Hashem AM, Damanhouri GA, et al. Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light. Transfusion. 2018; 58(1): 52–59.
- Hashem AM, Hassan AM, Tolah AM, et al. Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med. 2019; 29(6): 434–441.
- Keil SD, Ragan I, Yonemura S, et al. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang. 2020; 115(6): 495–501.
- Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020; 5(12): 1598–1607.
- Zhu L, Xu X, Zhu B, et al. Kinetics of SARS-CoV-2 specific and neutralizing antibodies over seven months after symptom onset in COVID-19 patients. Microbiol Spectr. 2021; 9(2): e0059021.
- Horby PW, Estcourt L, Peto L, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10289): 2049–2059.
